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Abstract 
NUP98 is considered as one of the most 
promiscuous genes in hematologic malignancies 
due to its participation in chromosomal 
translocations with up to 30 different partner genes, 
including homeodomain transcription factors. 
Keywords 
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Identity 
Included are patients with 1q21-25 breakpoints and 
confirmed NUP98 rearrangement. 
Clinics and pathology 
Disease 
Acute myeloid leukemia (AML), probably 
treatment related and chronic myeloid leukemia 
(CML) in progression. 
Figure 1.  Partial karyotypes with t(1;11)(q24;p15) (A). Fluorescence in situ hybridization with SureFISH NUP98 probe revealing 
rearrangement of the gene on metaphase and interphase cells (B) 
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Figure 2.  Karyotype of our unpublished case with t(1;11)(q24;p15) (arrows). 
 
Etiology 
Acute myeloid leukemia in 4: 2 patients with AML 
with maturation (AML-M2), in 1 of them that 
developed 3 years after the start of chemotherapy 
(MACOP-B) for stage III non-Hodgkin lymphoma 
(NHL)(immunoblast type)  (Nakamura et al., 1999; 
Hatano et al., 2000) and in the other it was 
diagnosed 3 years after chemotherapy (ifosfamide, 
adriamycin, cytoxan, etopside) and radiotherapy for 
sarcoma of the testis (Soares et al., 2006). 1 patient 
was diagnosed with AML with minimal maturation 
(AML-M1) who received chemotherapy 
(adriamycin, cytoxan, 5-FU) and bone marrow 
transplantation for breast adenocarcinoma (Kobzev 
et al., 2004), 1 with myelodysplastic syndrome 
evolving into acute myelomonocytic leukemia (M4) 
that developed after chemotherapy (doxorubicin, 
ifosfamide) and radiotherapy for liposarcoma with 
the latency period from chemotherapy to the onset 
of MDS (treated with azacytidine) 30 months and 
of AML 38 months (Zhang et al., 2007). 2 patients 
had CML in transformation, 1 of them on hydrea 
and myleran therapy (Kobzev et al., 2004) and the 
other received hydroxyurea during the chronic 
phase and chemotherapy (arabinosylcytosine, 
aclamycin, daunarubicin) during transformation that 
developed after 2.5 years of chronic phase (Bai et 
al., 2006). Our unpublished case received 
chemotherapy (MECOB-P) for B-cell NHL and 
developed chronic myelomonocytic leukemia 
(CMML) 18 month later. 
Epidemiology 
5 patients with confirmed NUP98 rearrangement (4 
males and 1 female aged 42 to 74 years, median 51 
years) (Hatano et al., 2000 Kobzev et al., 2004; Bai 
et al., 2006; Zhang et al., 2007) and an 18 years old 
male without molecular studies (Soares et al., 
2006). NUP98 rearrangement was also detected in a 
36 years old male (unpublished data). 
Evolution 
In 1 AML-M2 patient, complete remission of 
leukemia was achieved, but the NHL relapsed and 
an advanced gastric carcinoma was found and the 
patient died shortly afterwards (Hatano et al., 2000) 
and the other patient with AML-M2 died 5 months 
after leukemia onset (Soares et al., 2006). The 2 
other AML patients died shortly after the onset of 
leukemia (Kobzev et al., 2004; Zhang et al., 2007) 
as well as the patient with CML in transformation 
(Kobzev et al., 2004). From these data it appears 
that the clinical course of patients is quite 
aggressive and the prognosis is dismal. 
Cytogenetics 
Cytogenetics morphological 
Patients had variable breakpoints assigned to 
chromosome 1q, but FISH and/or molecular studies 
confirmed the involvement of PRRX1 that is 
mapped to 1q24.2, therefore chromosome 1 
breakpoints in patients were the same. 
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Additional anomalies 
Sole anomaly in 1 AML (Kobzev et al., 2004) and 
in 1 patient during the MDS phase (Zhang et al., 
2007); found in association with limited anomalies 
in the remaining AML patients:  +8 (Zhang et al., 
2007) and del(7q)/+8 subsequently acquired during 
MDS progression (Zhang et al., 2007). Sole 
additional anomaly to t(9;22)(q34;q11) in both 
progressed CML patients (Kobzev et al., 2004; Bai 
et al., 2006); found as the only karyotypic anomaly 
in  our unpublished case. 
Genes involved and 
proteins 
Note 
This translocation appears to be closely related to 
other translocations involving NUP98 and an 
homeodomain bearing protein, i.e. the 
t(2;11)(q31;p15),.with HOXD13 or with HOXD11 
involvement, the t(7;11)(p15;p15),.with HOXA9 or 
with HOXA13 involvement, the t(9;11)(q34;p15), 
with PRRX2 involvement, and the 
t(11;12)(p15;q13) with HOXC11 or with HOXC13 
involvement 




Part of a homeobox gene family that encode 
evolutionarily conserved transcription factors; 
contain the DNA binding homeodomain; function 
as a transcription factor and has a role in regulation 
of developmental processes. In contrast to clustered 
HOX genes, PRRX1 is not implicated in normal 
hematopoiesis or leukemogenesis; PRRX1 contains 
5 exons spanning 76 kb; the homeodomain of 
PRRX1 is located in exon 2. Member of the paired 
family of homeobox proteins localized to the 
nucleus; functions as a transcription co-activator. 




Encodes a 98 kDa nuclear pore transport protein 
that is a component of the nuclear pore complex 
mediating transport of mRNA and proteins between 
the nucleus and the cytoplasm. Two major NUP98 
transcripts of 4.0 and 7.0 kb can be detected and 
several minor transcripts are produced through 
alternative splicing. Belongs to a subgroup of 
nuclear pore proteins characterized by 
phenylalanine-glycine repeats (FG repeats), located 
in the N-terminus which are docking sites for 
transport receptors that play role in transport 
through the nuclear pore complex; the C-terminal 
auto-proteolytic domain contain a GLEBS-like 
motif and a RNP binding motif, surrounded by 
charged residues; may also function as a nuclear 
localization signal (Bai et al., 2006). 




5'-NUP98/PRRX1-3'. In frame fusion of NUP98 




The juxtaposition of the part of the DNA-binding 
homeodomain of PRRX1 to the N-terminal GLFG 
repeats of NUP98 leads to the generation of 
leukemogenic NUP98/PRRX1 fusion protein; the 
PRRX1 homeodomain may be upregulated. 
Oncogenesis 
Chromosomal translocations of the nucleoporin 
NUP98 gene have been described in de novo and 
therapy-related hematopoietic malignancies, in 
particular acute myeloid leukemia.  
The formation of chromosomal rearrangements that 
generate NUP98 fusion proteins suggests that 
aberrant expression of NUP98 fusion proteins may 
be a causal event for leukemic transformation. In all 
of the leukemia-associated NUP98 fusions 
described thus far, the FG repeats of NUP98 are 
always retained, thus they are capable of interacting 
with HDAC1 and CREBBP that may enable them 
to act as both trans-activators and trans-repressors. 
(Bai et al., 2006).  
NUP98/PRRX1 generated by t(1;11)(q24.2;p15.4) 
shares these features with other NUP98 chimeric 
proteins, suggesting that the FG repeats on its N-
terminus possess a critical role in leukemic 
transformation. Notably, all described patients with 
this rearrangement had a history of malignant tumor 
and leukemia developed after chemotherapy with 
topoisomerase II inhibitors and alkylating agents. 
Therefore, it is likely that the NUP98 locus is 
vulnerable to genotoxic induced chromosomal 
rearrangements. 
References 
Bai XT, Gu BW, Yin T, Niu C, Xi XD, Zhang J, Chen Z, 
Chen SJ. Trans-repressive effect of NUP98-PMX1 on 
PMX1-regulated c-FOS gene through recruitment of 
histone deacetylase 1 by FG repeats. Cancer Res. 2006 
May 1;66(9):4584-90 
Hatano Y, Miura I, Kume M, Miura AB. Translocation 
(1;11)(q23;p15), a novel simple variant of translocation 
(7;11)(p15;p15), in a patient with AML (M2) accompanied 
by non-Hodgkin lymphoma and gastric cancer. Cancer 
Genet Cytogenet. 2000 Feb;117(1):19-23 






Atlas Genet Cytogenet Oncol Haematol. 2019; 23(1) 24 
 
Kobzev YN, Martinez-Climent J, Lee S, Chen J, Rowley 
JD. Analysis of translocations that involve the NUP98 gene 
in patients with 11p15 chromosomal rearrangements. 
Genes Chromosomes Cancer. 2004 Dec;41(4):339-52 
Nakamura T, Yamazaki Y, Hatano Y, Miura I. NUP98 is 
fused to PMX1 homeobox gene in human acute 
myelogenous leukemia with chromosome translocation 
t(1;11)(q23;p15). Blood. 1999 Jul 15;94(2):741-7 
Soares EM, Santos N, de Araújo Silva Amaral B, Silva ML, 
Leite EP, Silva MO, Muniz MT, Ribeiro RC, de Morais VL, 
de Jesus Marques Salles T. Secondary acute myeloid 
leukemia with a t(1;11)(q23;p15) in an adolescent treated 
for testicular sarcoma. Cancer Genet Cytogenet. 2006 
Aug;169(1):83-5 
Zhang L, Alsabeh R, Mecucci C, La Starza R, Gorello P, 
Lee S, Lill M, Schreck R. Rare t(1;11)(q23;p15) in therapy-
related myelodysplastic syndrome evolving into acute 
myelomonocytic leukemia: a case report and review of the 
literature. Cancer Genet Cytogenet. 2007 Oct 1;178(1):42-
8 
This article should be referenced as such: 
Zamecnikova A. t(1;11)(q24;p15) NUP98/PRRX1. Atlas 
Genet Cytogenet Oncol Haematol. 2019; 23(1):21-24. 
